The ‘‘Microbial Contract Biomanufacturing Market, 2020-2030< RootsAnalysis>
Key Inclusions
§ A detailed review of the current landscape of companiesoffering contract manufacturing services for biologics, using microbialexpression systems, along with information on their year of establishment,company size, location of headquarters, number and location of their productionfacilities, scale of operation (preclinical, clinical and commercial), type ofbiologic(s) manufactured (peptides / proteins, antibodies, vaccines,biosimilars, oligonucleotides, plasmid DNA and others), type of microbialexpression system(s) used (bacterial, yeast and others), type of fermenter(s)employed (single-use fermenters, stainless steel fermenters and others), typeof manufacturing service(s) offered (cell banking, process development andcharacterization, analytical method development and testing, quality assuranceand control, scale-up, downstream processing and regulatory support), andregulatory accreditations / certifications received (if any).
§ A region-wise, company competitiveness analysis,highlighting key players engaged in microbial based contract manufacturingbased on their experience (considering the year of establishment of the firm)and expertise (taking into account their service portfolio, number of differenttypes of biologics manufactured and number of distinct expression system(s)used).
§ An analysis of the various partnerships signed within thisdomain, with a focus on microbial contract biomanufacturing, since 2016, basedon several relevant parameters, such as year of partnership, type ofpartnership model adopted, scale of operation, type of biologic, focus area,therapeutic area, most active players (in terms of number of partnershipssigned), and geography. Further, it features a detailed analysis of the variousmergers and acquisitions that were carried out in this domain, highlighting thetrend in terms of number of players acquired between 2016-2020 (till May),along with the geographical distribution of this activity.
§ An elaborate analysis of the various expansion initiativesundertaken by contract manufacturers using microbial expression systems inorder to augment their capabilities, over the period 2016-2020 (till May),taking into consideration several relevant parameters, such as year ofexpansion, type of expansion (capability expansion, capacity expansion,facility expansion and new facility), scale of operation of manufacturingfacility, type of biologic and location of manufacturing facility.
§ A review of the varied microbial based manufacturinginitiatives undertaken by big pharma players (shortlisted from the top 20pharmaceutical companies as of 2019), highlighting trends across variousparameters, such as number of initiatives, year of initiative and type ofinitiative.
§ A detailed proprietary 2×2 representation that wasdeveloped to assess the current market scenario (in terms of existingcompetition and growth opportunities) across emerging and established marketsegments.
§ Elaborate profiles of key players that offer contractbiomanufacturing services using microbial expression systems across differentgeographies, namely North America, Europe and Asia Pacific. Each profilefeatures a brief overview of the company, information related to its serviceportfolio, manufacturing capabilities and facilities, recent developments andan informed future outlook.
§ A discussion on industry affiliated trends, key drivers andchallenges, under a SWOT framework, which are likely to impact the evolution ofthis field. It also includes a Harvey ball analysis, highlighting the relativeimpact of each SWOT parameter on industry dynamics.
§ A case study comparing the key characteristics of largemolecule and small molecule drugs, along with details on the various stepsinvolved in their respective manufacturing processes.
§ An insightful discussion on the impact of COVID-19 outbreakon the overall microbial contract biomanufacturing market, and the keyinitiatives undertaken by CMOs to combat the challenges posed due to ongoingsituation.
The report alsofeatures the likely distribution of the current and forecasted opportunityacross important market segments, mentioned below:
§ Type of Product
§ API
§ FDF
§ Type of Biologic
§ Proteins
§ Enzymes
§ Growth Hormones
§ Antibody based Drugs
§ Others (plasmid DNA,probiotics, microbiome-based biologics)
§ Type of MicrobialExpression System
§ Bacteria
§ Yeast
§ Others (Algae andfungi)
§ Scale of Operation
§ Commercial
§ Preclinical /Clinical
§ Type of End User
§ Small Companies
§ Mid-sized Companies
§ Large / Very Large Companies
§ Key GeographicalRegions
§ North America
§ Europe
§ Asia Pacific
§ Middle East and NorthAfrica
§ Latin America
To request sample pages, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market/request-sample.html
Key Questions Answered
§ Who are the leadingCMOs with expertise in production of microbial biologics?
§ What are thepreferred microbial expression systems used in biologic development andmanufacturing?
§ What are the keymicrobial fermentation technology platforms?
§ Who could be thepotential partners for the microbial CMOs?
§ What kind ofpartnership models are commonly adopted by stakeholders engaged in this domain?
§ What type ofexpansion initiatives are being carried out by CMOs in this domain?
§ What initiatives arebeing undertaken by big pharma players in this domain?
§ What are the keyfactors influencing the make (manufacture in-house) versus buy (outsource)decision related to microbial fermentation?
§ What are the keytrends within the microbial contract biomanufacturing market?
§ How is the currentand future market opportunity likely to be distributed across key marketsegments?
You may also be interested inthe following titles:
1. DrugRepurposing Service Providers Market, 2020 – 2030
2. AntibodyDiscovery Services and Platforms Market (3rd Edition), 2020-2030
3. LiveBiotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on ActivePharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
